Ozempic for Heart Failure: Who Is (and Isn't) a Good Candidate

What You Need to Know First: Off-Label Status and Why It Matters

Semaglutide (Ozempic) carries FDA approval for type 2 diabetes management and, as Wegovy, for chronic weight management in adults with obesity or overweight plus a weight-related comorbidity. Heart failure is not on that approval list for either formulation. Any clinician prescribing Ozempic for heart failure is doing so off-label, which means the prescriber takes on direct responsibility for patient selection, monitoring, and informed consent.

That distinction matters for you practically. Insurance coverage is less reliable. Dose titration protocols are borrowed from diabetes and obesity trials rather than a dedicated heart failure label. And the body of evidence, while genuinely promising, is still early.

The signal that brought cardiology and obesity medicine together here is real: GLP-1 receptor agonists appear to reduce cardiac inflammation, improve natriuretic peptide levels, and lower body weight in ways that ease the mechanical burden on a failing heart. For women, who carry a disproportionate burden of the HFpEF phenotype, that signal deserves careful attention.

The Core Evidence: What the Trials Actually Show

STEP-HFpEF: The Key Study You Should Know By Name

The STEP-HFpEF trial, published in the New England Journal of Medicine in 2023, enrolled 529 adults with HFpEF (ejection fraction ≥45%) and a BMI ≥30. Participants received semaglutide 2.4 mg weekly (as Wegovy) or placebo for 52 weeks. The primary endpoints were Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and body weight change.

Results were clear. The semaglutide group achieved a mean body weight reduction of 13.3% vs. 2.6% with placebo, and KCCQ-CSS improved by 16.6 points vs. 8.7 points. Six-minute walk distance also improved by roughly 20 meters more than placebo. These are clinically meaningful numbers for a population with significant functional limitation.

Women made up approximately 43% of the STEP-HFpEF cohort. Subgroup analyses did not show a statistically significant sex-based interaction, meaning the benefit appeared consistent across sexes, though the trial was not powered specifically for sex-stratified conclusions.

STEP-HFpEF DM: Extending the Evidence to Diabetes

The STEP-HFpEF DM trial, reported alongside STEP-HFpEF, enrolled 616 adults with HFpEF, BMI ≥30, and type 2 diabetes. Results were directionally similar: semaglutide reduced body weight by 9.8% vs. 3.4% with placebo, and KCCQ-CSS improved significantly. Together, the two trials provide the strongest available evidence base for this off-label application.

What We Do Not Yet Have

No completed randomized controlled trial has specifically examined Ozempic (the 0.5-to-2.0 mg diabetes formulation, dosed differently from Wegovy) as a primary heart failure intervention. The doses used in STEP-HFpEF were 2.4 mg weekly. When clinicians prescribe Ozempic off-label for heart failure, they are extrapolating from Wegovy data to a different commercial product with a different maximum approved dose. This is a genuine evidence gap, and the FDA has noted the distinction between formulations matters for labeling purposes.

Who Is a Good Candidate: Patient Selection Criteria

The following selection framework is based on available trial inclusion criteria, cardiology society guidance, and women's-health considerations. It is not a substitute for individualized clinical judgment by your care team.

Ejection Fraction Type: HFpEF, Not HFrEF

The evidence base is entirely in HFpEF (ejection fraction ≥45%). In heart failure with reduced ejection fraction (HFrEF, ejection fraction <40%), GLP-1 receptor agonists do not have the same supportive data. One earlier study, FIGHT (2016), found liraglutide (a related GLP-1 agent) did not improve outcomes in HFrEF and may have increased adverse events in that population.

If your echocardiogram shows a preserved or mildly reduced ejection fraction (HFpEF or HFmrEF, ejection fraction 41-49%), you are in the zone where the evidence exists. If your ejection fraction is below 40%, semaglutide for heart failure is not supported by current data.

Obesity as a Required Co-Condition

Both STEP-HFpEF trials required a BMI ≥30. This is not an arbitrary threshold. The proposed mechanisms by which semaglutide helps in HFpEF are largely mediated through weight reduction, reduced pericardial fat, lower filling pressures, and decreased systemic inflammation tied to adiposity. In individuals with HFpEF and a BMI <30, the evidence does not exist to justify off-label use.

Glycemic Status: Diabetes or Not

Both diabetic and non-diabetic patients showed benefit across the two STEP-HFpEF trials. You do not need a diabetes diagnosis to be a candidate, but the presence of type 2 diabetes does add a second approved indication for Ozempic that simplifies prescribing and insurance authorization.

Hemodynamic Stability: Decompensated Heart Failure Is a Contraindication

Active decompensated heart failure requiring IV diuresis, hospitalization, or vasopressors is not a safe setting for initiating semaglutide. All trial participants were clinically stable outpatients. Starting a GLP-1 agonist during decompensation can worsen nausea, compromise nutrition, and complicate fluid management.

Kidney Function Considerations

Semaglutide itself does not require dose adjustment for most stages of chronic kidney disease, and trial data suggest it may be nephroprotective at an eGFR ≥15 mL/min/1.73m². Still, women with HFpEF frequently have concurrent CKD, and cardiorenal interactions require careful monitoring. Your cardiologist and nephrologist should align before initiation.

Women-Specific Physiology: Why This Matters More Than You Think

HFpEF Is a Women's Disease

Women account for more than 60% of HFpEF cases, and the reasons are sex-specific. Estrogen has cardioprotective effects on myocardial stiffness, endothelial function, and inflammatory signaling. As estrogen levels fall during perimenopause and drop sharply after menopause, cardiac fibrosis accelerates and diastolic dysfunction becomes more likely. Women also develop HFpEF at older ages than men and carry more comorbidities including hypertension, obesity, and atrial fibrillation at the time of diagnosis.

Perimenopause and the HFpEF Risk Window

The perimenopausal transition, typically beginning in the mid-40s and lasting four to eight years, is a period of rapid hormonal flux that can accelerate metabolic and cardiac risk. Weight gain during perimenopause averages 1.5 kg per year, and this weight preferentially deposits as visceral and pericardial fat, the exact fat depot implicated in HFpEF pathophysiology.

Perimenopausal women with new-onset HFpEF and obesity are a population where semaglutide's dual action on weight and cardiac mechanics is biologically plausible. The evidence in this specific group is extrapolated from the broader STEP-HFpEF cohort, not directly studied in a perimenopause-specific trial. Clinicians should note this gap honestly.

Postmenopausal Women: The Primary STEP-HFpEF Phenotype

The average age in STEP-HFpEF was approximately 69 years, which means the majority of women enrolled were postmenopausal. This is where the evidence is strongest. Postmenopausal women with HFpEF, BMI ≥30, and stable symptoms on guideline-directed medical therapy represent the group most likely to benefit from off-label semaglutide.

Hormonal Interactions: What We Know and Don't

Semaglutide slows gastric emptying, which can alter absorption of oral medications including oral hormone therapy. Postmenopausal women on oral estradiol or oral conjugated equine estrogen should be aware that absorption timing may shift, though no dedicated pharmacokinetic study has quantified this interaction in women. Transdermal estradiol avoids the GI absorption issue entirely and is generally preferred in women with cardiovascular comorbidities per Menopause Society guidance.

Pregnancy, Lactation, and Contraception: Required Reading

Pregnancy: Contraindicated

Semaglutide is contraindicated during pregnancy. Animal reproductive studies showed fetal harm at exposures below the human therapeutic dose. Human data are limited but include case reports of adverse pregnancy outcomes associated with inadvertent GLP-1 agonist exposure. There is no safe dose in pregnancy.

If you are of reproductive age and being considered for semaglutide, your prescriber should discuss reliable contraception before you start. The drug should be discontinued at least two months before any planned conception, given its long half-life of approximately one week.

PCOS: A Complicating Factor

Women with PCOS have a higher baseline rate of obesity, metabolic syndrome, and insulin resistance, all of which increase lifetime cardiovascular risk, including HFpEF. Semaglutide is not approved for PCOS, but off-label use in reproductive-age women with PCOS and early metabolic heart disease is an emerging area. These women require especially careful contraception counseling because weight loss with GLP-1 agonists can restore ovulation and increase pregnancy risk unexpectedly, a phenomenon documented in PCOS literature.

Lactation

There are no adequate human studies of semaglutide in breastfeeding women. Animal data show transfer into milk. Given the unknown risk to a nursing infant and the availability of alternative therapies for weight management or diabetes in the postpartum period, semaglutide should not be used during breastfeeding unless the clinical situation is exceptional and clearly documented.

Who Is NOT a Good Candidate

Some contraindications and relative exclusions apply regardless of how compelling the weight-loss benefit appears:

• Personal or family history of medullary thyroid carcinoma or MEN2: this is an absolute contraindication for all GLP-1 receptor agonists per FDA labeling
• Active pancreatitis or a history of recurrent pancreatitis
• Decompensated heart failure: initiation during active fluid overload or cardiogenic shock
• HFrEF (ejection fraction <40%): no supportive trial data, possible harm signal from FIGHT
• BMI <30 without diabetes: outside the studied population
• Severe gastroparesis: semaglutide's gastric-emptying effects worsen this condition
• Pregnancy or active breastfeeding
• Renal replacement therapy (dialysis): insufficient safety data

Dosing Approach Off-Label: What the Evidence and Prescribers Use

Because the STEP-HFpEF trials used Wegovy (semaglutide 2.4 mg weekly), and Ozempic is approved only up to 2.0 mg weekly, a prescribing clinician using Ozempic off-label typically follows the standard Ozempic titration schedule:

• Weeks 1-4: 0.5 mg subcutaneous injection once weekly
• Week 5 onward: 1.0 mg weekly if tolerated
• Week 17 onward: 2.0 mg weekly if additional glycemic or weight control is needed

GI side effects (nausea, vomiting, constipation) are the most common reasons for dose reduction or discontinuation and are more common in women than men, likely related to sex differences in gastric motility. Women report GI adverse events at roughly 1.5-fold higher rates than men in GLP-1 agonist trials.

Starting low and titrating slowly is especially relevant in women with HFpEF, who may already have reduced appetite and lower caloric intake due to heart failure symptoms. Aggressive caloric restriction from nausea on top of heart failure cachexia risk requires monitoring.

Monitoring After Initiation

Your care team should track the following at regular intervals once semaglutide is started for heart failure:

Cardiac Monitoring

• Symptom trajectory: KCCQ score or 6-minute walk distance every 3-6 months
• Echocardiogram at baseline and at 12 months to assess diastolic function
• BNP or NT-proBNP at baseline and at 3-6 months
• Blood pressure: GLP-1 agonists modestly lower systolic blood pressure by 2-3 mmHg on average, which may require antihypertensive dose adjustment

Metabolic and Renal Monitoring

• HbA1c and fasting glucose at 3 months if diabetic
• Comprehensive metabolic panel including eGFR and electrolytes at 3-month intervals
• Weight and BMI at every visit

Nutritional Status

Heart failure with obesity and GLP-1-induced nausea creates a real risk of inadequate protein intake. A registered dietitian familiar with cardiac nutrition should be part of your team, especially if weight loss exceeds 1 kg per week.

The Evidence Gap Specific to Women: A Candid Assessment

Women have been historically underrepresented in heart failure trials. STEP-HFpEF enrolled 43% women, which is better than many cardiovascular trials but still leaves sex-stratified subgroup analyses underpowered. The JACC 2023 consensus statement on sex differences in HFpEF explicitly calls for trials powered to detect sex-specific treatment effects.

What we know directly: semaglutide reduces weight and improves KCCQ scores in a mixed-sex HFpEF population. What we are extrapolating: that the benefit is equivalent in women, that perimenopausal women respond similarly to postmenopausal women, and that the optimal dose (2.4 mg Wegovy vs. 2.0 mg Ozempic) produces equivalent cardiac benefit. None of those extrapolations have been directly tested.

As Dr. Elena Vasquez, WomanRx Editorial Board OB-GYN, notes: "The HFpEF phenotype in postmenopausal women is driven by a convergence of estrogen loss, visceral adiposity, and microvascular disease. GLP-1 agonists address the adiposity arm of that triad well. What we still lack is a trial that accounts for hormonal status at enrollment, which would tell us far more about who benefits most."

Real-World Considerations for Women Seeking Access

Getting Ozempic prescribed off-label for heart failure requires a motivated prescriber, usually a cardiologist or an obesity medicine physician working alongside cardiology. Steps that can help:

1. Have a recent echocardiogram confirming HFpEF (ejection fraction ≥45%) in your records
2. Document BMI ≥30 at your most recent visit
3. Bring evidence of stable, optimized guideline-directed medical therapy (diuretics, SGLT2 inhibitors if tolerated, exercise)
4. Ask your cardiologist specifically about STEP-HFpEF trial results and whether you match the enrollment criteria
5. Check your insurance formulary: Wegovy may actually be easier to authorize than Ozempic for a non-diabetes indication, because Wegovy is approved for obesity

SGLT2 inhibitors (empagliflozin, dapagliflozin) are now guideline-recommended for HFpEF with a far stronger evidence base and FDA approval. The 2022 AHA/ACC heart failure guidelines give SGLT2 inhibitors a Class 2a recommendation for HFpEF. Semaglutide should be considered additive to, not a replacement for, these established therapies.